NCT07146906View on ClinicalTrials.gov

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 18, 2025

Primary Completion Date

April 9, 2030

Study Completion Date

July 16, 2030

Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
BIOLOGICAL

zigakibart

zigakibart 600 mg sc injections every second week for 104 weeks (2 years)

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY